deltatrials
Completed PHASE3 NCT00563368

A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults

A Phase III, Randomized, Double-Blind, Parallel-Design Study Comparing Multiple Doses of VI-0521 to Placebo and Their Single-Agent Phentermine and Topiramate Constituents for the Treatment of Obesity in Adults

Sponsor: Medpace, Inc.

Conditions Obesity
Interventions VI-0521 phentermine topiramate
Updated 7 times since 2017 Last updated: Mar 10, 2015 Started: Dec 31, 2007 Primary completion: Sep 30, 2008 Completion: Sep 30, 2008

A PHASE3 clinical study on Obesity, this trial is completed. The trial is conducted by Medpace, Inc. and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Mar 2022 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Medpace, Inc.
  • VIVUS LLC
Data source: VIVUS LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Durham, United States
  • • Philadelphia, United States